Fig. 2.

STIV entry is mediated through a non-caveola- and cholesterol-dependent pathway. (A) Fluorescence microscopy of EGFP-STIV-infected cells after treatment with DMSO, βMCD, nystatin or filipin III. (B) Determination of the fluorescence intensity of EGFP-STIV-infected cells after treatment with DMSO, βMCD, nystatin or filipin III. (C) Quantitative analysis of the percentage of EGFP-STIV-infected cells by flow cytometry. (D) Western blotting detection of protein synthesis of the STIV major capsid protein after treatment with βMCD